z-logo
open-access-imgOpen Access
Characterization of the relationship between FLI1 and immune infiltrate level in tumour immune microenvironment for breast cancer
Author(s) -
Wang Shiyuan,
Wang Yakun,
Yu Chunlu,
Cao Yiyin,
Yu Yao,
Pan Yi,
Su Dongqing,
Lu Qianzi,
Yang Wuritu,
Zuo Yongchun,
Yang Lei
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15205
Subject(s) - immune system , breast cancer , fli1 , cancer research , immunotherapy , biology , cancer , immunology , cancer immunotherapy , tumor microenvironment , gene , transcription factor , genetics
Abstract Breast cancer is the most common cancer and the leading cause of cancer death among women in the world. Tumour‐infiltrating lymphocytes were defined as the white blood cells left in the vasculature and localized in tumours. Recently, tumour‐infiltrating lymphocytes were found to be associated with good prognosis and response to immunotherapy in tumours. In this study, to examine the influence of FLI1 in immune system in breast cancer, we interrogated the relationship between the FLI1 expression levels with infiltration levels of 28 immune cell types. By splitting the breast cancer samples into high and low expression FLI1 subtypes, we found that the high expression FLI1 subtype was enriched in many immune cell types, and the up‐regulated differentially expressed genes between them were enriched in immune system processes, immune‐related KEGG pathways and biological processes. In addition, many important immune‐related features were found to be positively correlated with the FLI1 expression level. Furthermore, we found that the FLI1 was correlated with the immune‐related genes. Our findings may provide useful help for recognizing the relationship between tumour immune microenvironment and FLI1, and may unravel clinical outcomes and immunotherapy utility for FLI1 in breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here